Pharmaceuticals

A Growing Focus On Personalized Medicine Fueling The Growth Of The Market Due To Improved Treatment Outcomes And Tailored Therapies Is Supporting Development Across The Fabry Disease Market

May 19, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Fabry Disease Market During The Forecast Period?

The market size for Fabry disease has shown significant expansion in recent years. It is projected to increase from $2.26 billion in 2025 to $2.43 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.7%. The surge during the historical period can be attributed to factors such as elevated awareness of rare genetic disorders, the approval of enzyme replacement therapies, the establishment of more specialty clinics, the expansion of genetic screening initiatives, and an increase in diagnosis rates.

The Fabry disease market is projected to experience substantial expansion in the coming years, reaching a valuation of **$3.27 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%.** This anticipated growth during the forecast period is primarily driven by advancements in gene-based therapies, the proliferation of newborn screening programs, a rise in healthcare expenditures for rare diseases, the evolution of personalized medicine, and the emergence of next-generation oral treatments. Key trends anticipated for the forecast period encompass a greater uptake of enzyme replacement therapy, heightened attention on rare disease diagnosis, an increasing reliance on genetic testing for early detection, the broadening scope of oral and adjunct therapies, and the adoption of more patient-centric treatment strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp

Which Growth Drivers Are Expected To Support The Fabry Disease Market Forward?

An increasing emphasis on personalized medicine is projected to propel the expansion of the fabry disease market in the future. Personalized medicine defines a treatment methodology that utilizes information regarding an individual’s genetic characteristics, environmental factors, and lifestyle to customize medical care and therapies specifically for them, aiming for enhanced outcomes. The escalating attention on personalized medicine is fueled by its capacity to improve treatment effectiveness and minimize side effects by tailoring therapies to meet individual patient requirements. It assists in customizing treatment plans based on a patient’s unique genetic mutation and the severity of their disease, thereby improving outcomes and reducing unnecessary side effects. For instance, in February 2024, the US-based non-profit organization, the Personalized Medicine Coalition, highlighted that in 2023, the FDA granted approval for 16 new personalized treatments for rare disease patients, which represented a substantial increase from the six approvals in 2022. As a result, a heightened focus on personalized medicine is driving the growth of the fabry disease market.

How Is The Fabry Disease Market Structured Across Different Market Segments?

The fabry disease market covered in this report is segmented –

1) By Type: Type 1, Type 2, Other Types

2) By Treatment: Enzyme Replacement Therapy, Oral Therapy, Adjunct Therapy, Other Treatments

3) By Diagnosis: Blood Test, Genetic Test, Other Diagnosis

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Type 1: Classic Fabry Disease, Later-Onset Fabry Disease

2) By Type 2: Cardiovascular-Focused Fabry Disease, Renal-Focused Fabry Disease

3) By Other Types: Variant Fabry Disease, X-linked Fabry Disease

What Trends Are Affecting The Fabry Disease Market Dynamics?

Major companies operating in the Fabry disease market are focusing on developing innovative therapies, such as PEGylated enzyme replacement therapy (ERT), to improve treatment effectiveness, enhance patient adherence, and lessen immunogenic reactions associated with conventional ERTs. PEGylated enzyme replacement therapy (ERT) is a modified version of traditional ERT where polyethylene glycol (PEG) chains are attached to the enzyme to boost its stability, extend its circulation time in the body, and reduce immune system responses. For instance, in May 2023, Chiesi Global Rare Diseases, a division of the Italy-based pharmaceutical company Chiesi Group, announced that the U.S. Food and Drug Administration (FDA), a US-based government agency, had approved PRX-102 (pegunigalsidase alfa) for the treatment of adult Fabry disease patients. This approval is backed by a robust clinical program involving over 140 patients and long-term follow-up of up to 7.5 years, which demonstrated the therapy’s efficacy in reducing renal Gb3 deposits and maintaining kidney function while also showing a favorable safety profile.

Which Organizations Are Involved In The Fabry Disease Market?

Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH

Access The Complete Fabry Disease Market Report:

https://www.thebusinessresearchcompany.com/report/fabry-disease-global-market-report

Which Region Stands As The Largest Contributor To The Fabry Disease Market?

North America was the largest region in the fabry disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Fabry Disease Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24218&type=smp

Browse Through More Reports Similar to the Global Fabry Disease Market 2026, By The Business Research Company

Fabry Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/fabry-disease-treatment-global-market-report

Gauchers Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/gauchers-disease-global-market-report

Carcinoembryonic Antigen Market Report 2026

https://www.thebusinessresearchcompany.com/report/carcinoembryonic-antigen-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795